These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 25343125

  • 1. Current treatment of atypical hemolytic uremic syndrome.
    Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L.
    Intractable Rare Dis Res; 2014 May; 3(2):34-45. PubMed ID: 25343125
    [Abstract] [Full Text] [Related]

  • 2. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [Abstract] [Full Text] [Related]

  • 3. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [Abstract] [Full Text] [Related]

  • 4. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 5. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Jul; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 6. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M, Go RS, Willrich MAV.
    J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
    [Abstract] [Full Text] [Related]

  • 7. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome.
    Shen YM.
    Thromb J; 2016 Oct; 14(Suppl 1):19. PubMed ID: 27766045
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 9. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD.
    Praxis (Bern 1994); 2016 Mar 30; 105(7):389-96. PubMed ID: 27005733
    [Abstract] [Full Text] [Related]

  • 10. [Atypical hemolytic uremic syndrome].
    Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM.
    Med Clin (Barc); 2015 Nov 20; 145(10):438-45. PubMed ID: 25433773
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
    Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S.
    Pediatr Nephrol; 2011 Aug 20; 26(8):1325-9. PubMed ID: 21556717
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 20; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 13. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
    Kerboua KE, Haiba F, Batouche D.
    J Immunoassay Immunochem; 2017 Dec 20; 38(2):178-189. PubMed ID: 27617501
    [Abstract] [Full Text] [Related]

  • 14. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
    Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A.
    Ther Apher Dial; 2019 Feb 20; 23(1):4-21. PubMed ID: 30294946
    [Abstract] [Full Text] [Related]

  • 15. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A, Nayer A, Haas CS.
    J Nephrol; 2017 Jun 20; 30(3):347-362. PubMed ID: 27848226
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F, Frémeaux-Bacchi V, Loirat C.
    Eur J Intern Med; 2013 Sep 20; 24(6):492-5. PubMed ID: 23756030
    [Abstract] [Full Text] [Related]

  • 20. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 20; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.